Literature DB >> 11167281

The effect of early steroid treatment after PRK on clinical and refractive outcomes.

M Vetrugno1, A Maino, G M Quaranta, L Cardia.   

Abstract

PURPOSE: To evaluate the effects of steroid treatment administered in the first days after excimer laser keratectomy (PRK) on re-epithelialization time, postoperative pain, haze and refractive outcome.
METHODS: A randomised, double masked trial was carried out on two groups of patients (40 patients each), who underwent PRK. Group A (steroid group) received 0.1% fluorometholone acetate whereas group B (NSAID group) received 0.5% ketorolac tromethamine until re-epithelialization was completed. Subsequently, all 80 patients received the same steroid treatment: 0.1%, fluorometholone acetate for myopic corrections up to -5 D, or dexamethasone for myopic corrections exceeding -5 D. Both drugs were tapered off over approximately 3 months. Follow-up examinations were planned at 1, 3, 6, 12 months after surgery.
RESULTS: Re-epithelialization was completed after three days, without any significant difference between groups. A higher hyperopic shift was shown in the steroid group and a more severe regression was reported in the NSAID group (p<0.001). Haze was significantly reduced in the steroid group (p=0.005), especially for myopic corrections over -5 D (p=0.015). Pain was significantly reduced in the NSAID group (p=0.002).
CONCLUSION: Steroid eyedrops administered in the first days after PRK did not affect re-epithelialization time. Moreover, a modulation of the inflammatory response in this period appears to reduce haze and myopic regression in high myopic patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167281     DOI: 10.1034/j.1600-0420.2001.079001023.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  16 in total

Review 1.  Corneal Regeneration After Photorefractive Keratectomy: A Review.

Authors:  Javier Tomás-Juan; Ane Murueta-Goyena Larrañaga; Ludger Hanneken
Journal:  J Optom       Date:  2014-10-23

2.  Reducing peak corneal haze after photorefractive keratectomy in rabbits: prednisolone acetate 1.00% versus cyclosporine A 0.05%.

Authors:  Chyong Jy Nien; Kevin J Flynn; Melissa Chang; Donald Brown; James V Jester
Journal:  J Cataract Refract Surg       Date:  2011-03-15       Impact factor: 3.351

3.  Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis).

Authors:  Edward E Manche; Weldon W Haw
Journal:  Trans Am Ophthalmol Soc       Date:  2011-12

4.  Optical effects of anti-TGFbeta treatment after photorefractive keratectomy in a cat model.

Authors:  Jens Bühren; Lana Nagy; Jennifer N Swanton; Shawn Kenner; Scott MacRae; Richard P Phipps; Krystel R Huxlin
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-24       Impact factor: 4.799

5.  [Corneal wound healing after hyperopic PRK and LASIK].

Authors:  T Hammer; S Giessler; G I W Duncker; E Peschke
Journal:  Ophthalmologe       Date:  2005-01       Impact factor: 1.059

6.  The incidence of central serous chorioretinopathy after photorefractive keratectomy and laser in situ keratomileusis.

Authors:  Majid Moshirfar; Maylon Hsu; Julia Schulman; Joseph Armenia; Shameema Sikder; M Elizabeth Hartnett
Journal:  J Ophthalmol       Date:  2012-02-12       Impact factor: 1.909

7.  Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?

Authors:  Uwe Pleyer; Paul G Ursell; Paolo Rama
Journal:  Ophthalmol Ther       Date:  2013-09-17

8.  Effect of different treatment regimen with dexamethasone and acetylcysteine on corneal wound healing in rabbits.

Authors:  Ali Asghar Sarchahi; Abdolhamid Meimandi Parizi; Masoomeh Eghtedari; Salar Keshavarz
Journal:  Iran J Med Sci       Date:  2011-09

9.  Use of loteprednol for routine prophylaxis after photorefractive keratectomy.

Authors:  Mark D Mifflin; Lisa L Leishman; Steven M Christiansen; Shameema Sikder; Maylon Hsu; Majid Moshirfar
Journal:  Clin Ophthalmol       Date:  2012-05-01

10.  Topical rosiglitazone is an effective anti-scarring agent in the cornea.

Authors:  Krystel R Huxlin; Holly B Hindman; Kye-Im Jeon; Jens Bühren; Scott MacRae; Margaret DeMagistris; David Ciufo; Patricia J Sime; Richard P Phipps
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.